

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/apm-21-999">https://dx.doi.org/10.21037/apm-21-999</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared, and we also found PD-1 inhibitors may be safe for the treatment of HCC before LT when the interval between the two treatments is sufficient.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists and liver surgeons who are interested in studies of PD-1.
8	For what type of analysis or purpose?	The clinical characteristics, imaging findings, and outcomes of 5 LT patients who had a history of HCC and received anti-PD-1 therapy.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: chenmg3@mail.sysu.edu.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.